Skip to content
10-Q

Quarterly Report

Arcadia Biosciences, Inc. RKDA

0000950170-25-066425

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 1.37M sh
Capex Q1 2025 · Mar 31, 2025 $0
Capex Q1 2025 · Mar 31, 2024 $13K
Cash And Equivalents Q1 2025 · Mar 31, 2025 $3.16M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $4.24M
Current Liabilities Q1 2025 · Mar 31, 2025 $2.22M
Current Liabilities Q1 2025 · Dec 31, 2024 $2.56M
Total Liabilities Q1 2025 · Mar 31, 2025 $4.09M
Total Liabilities Q1 2025 · Dec 31, 2024 $7.29M
Current Assets Q1 2025 · Mar 31, 2025 $8.85M
Current Assets Q1 2025 · Dec 31, 2024 $9.24M
Total Assets Q1 2025 · Mar 31, 2025 $12.99M
Total Assets Q1 2025 · Dec 31, 2024 $13.52M
Rd Expense Q1 2025 · Mar 31, 2025 $0
Rd Expense restated Q1 2025 · Mar 31, 2024 $6K
Operating Cash Flow Q1 2025 · Dec 31, 2024 −$9.6M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$3.21M
Shares Diluted Q1 2025 · Mar 31, 2024 1.36M sh
Eps Diluted Q1 2025 · Mar 31, 2024 −$1.78
Eps Basic Q1 2025 · Mar 31, 2024 −$1.78
Sga Expense restated Q1 2025 · Mar 31, 2024 $2.06M
Net Income Q1 2025 · Mar 31, 2024 −$2.42M
Operating Income restated Q1 2025 · Mar 31, 2024 −$1.59M
Cost Of Revenue restated Q1 2025 · Mar 31, 2024 $471K
Revenue restated Q1 2025 · Mar 31, 2024 $987K